Do analysts recommend SLXN or ADXN?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Silexion Therapeutics 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Addex Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is SLXN or ADXN more profitable?

Addex Therapeutics' return on equity of -105.98% beat Silexion Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Silexion Therapeutics N/A -516.86% -176.68% Addex Therapeutics N/A -105.98% -87.61%

Does the media prefer SLXN or ADXN?

In the previous week, Addex Therapeutics had 1 more articles in the media than Silexion Therapeutics. MarketBeat recorded 3 mentions for Addex Therapeutics and 2 mentions for Silexion Therapeutics. Silexion Therapeutics' average media sentiment score of 1.92 beat Addex Therapeutics' score of 0.39 indicating that Silexion Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Silexion Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Addex Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts recommend SLXN or CELZ?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Silexion Therapeutics 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Creative Medical Technology 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50

Is SLXN or CELZ more profitable?

Creative Medical Technology's return on equity of -88.38% beat Silexion Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Silexion Therapeutics N/A -516.86% -176.68% Creative Medical Technology N/A -88.38% -84.71%

Do analysts rate SLXN or OBSV?

Given ObsEva's higher possible upside, analysts plainly believe ObsEva is more favorable than Silexion Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Silexion Therapeutics 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 ObsEva 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has better earnings & valuation, SLXN or OBSV?

Silexion Therapeutics is trading at a lower price-to-earnings ratio than ObsEva, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Silexion Therapeutics N/A N/A -$11.91M -$80.50 N/A ObsEva N/A N/A -$58.38M -$0.92 N/A

Is SLXN or OBSV more profitable?

ObsEva's return on equity of -416.36% beat Silexion Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Silexion Therapeutics N/A -516.86% -176.68% ObsEva N/A -416.36% -92.01%

Do analysts rate SLXN or PMCB?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Silexion Therapeutics 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Nuvilex 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has higher earnings & valuation, SLXN or PMCB?

Nuvilex is trading at a lower price-to-earnings ratio than Silexion Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Silexion Therapeutics N/A N/A -$11.91M -$80.50 N/A Nuvilex N/A N/A $30.66M -$1.12 N/A

Is SLXN or PMCB more profitable?

Nuvilex's return on equity of 2.13% beat Silexion Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Silexion Therapeutics N/A -516.86% -176.68% Nuvilex N/A 2.13% 1.69%

Do analysts recommend SLXN or NKGN?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Silexion Therapeutics 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 NKGen Biotech 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has stronger earnings & valuation, SLXN or NKGN?

NKGen Biotech is trading at a lower price-to-earnings ratio than Silexion Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Silexion Therapeutics N/A N/A -$11.91M -$80.50 N/A NKGen Biotech N/A N/A -$82.94M -$1.51 N/A

Is SLXN or NKGN more profitable?

NKGen Biotech's return on equity of 0.00% beat Silexion Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Silexion Therapeutics N/A -516.86% -176.68% NKGen Biotech N/A N/A -479.36%

Silexion Therapeutics (SLXN) Competitors

$3.09 +0.03 (+0.98%)

Closing price 04:00 PM Eastern

Extended Trading

$3.05 -0.04 (-1.42%)

As of 07:58 PM Eastern

Compare

SLXN vs. ADXN, CELZ, OBSV, PMCB, and NKGN

Should you buy Silexion Therapeutics stock or one of its competitors? MarketBeat compares Silexion Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Silexion Therapeutics include Addex Therapeutics (ADXN), Creative Medical Technology (CELZ), ObsEva (OBSV), Nuvilex (PMCB), and NKGen Biotech (NKGN). These companies are all part of the "pharmaceutical products" industry.

How does Silexion Therapeutics compare to Addex Therapeutics?

Silexion Therapeutics (NASDAQ:SLXN) and Addex Therapeutics (NASDAQ:ADXN) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, media sentiment, risk, profitability, institutional ownership, analyst recommendations, earnings and valuation.

Silexion Therapeutics has a beta of -0.32, indicating that its share price is 132% less volatile than the broader market. Comparatively, Addex Therapeutics has a beta of 1.48, indicating that its share price is 48% more volatile than the broader market.

Addex Therapeutics has higher revenue and earnings than Silexion Therapeutics. Addex Therapeutics is trading at a lower price-to-earnings ratio than Silexion Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Silexion Therapeutics	N/A	N/A	-$11.91M	-$80.50	N/A
Addex Therapeutics	$210K	36.34	-$8.12M	-$5.74	N/A

In the previous week, Addex Therapeutics had 1 more articles in the media than Silexion Therapeutics. MarketBeat recorded 3 mentions for Addex Therapeutics and 2 mentions for Silexion Therapeutics. Silexion Therapeutics' average media sentiment score of 1.92 beat Addex Therapeutics' score of 0.39 indicating that Silexion Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Silexion Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Addex Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Addex Therapeutics' return on equity of -105.98% beat Silexion Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Silexion Therapeutics	N/A	-516.86%	-176.68%
Addex Therapeutics	N/A	-105.98%	-87.61%

11.0% of Silexion Therapeutics shares are owned by institutional investors. Comparatively, 16.1% of Addex Therapeutics shares are owned by institutional investors. 5.0% of Silexion Therapeutics shares are owned by company insiders. Comparatively, 15.0% of Addex Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Silexion Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Addex Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Addex Therapeutics beats Silexion Therapeutics on 9 of the 13 factors compared between the two stocks.

How does Silexion Therapeutics compare to Creative Medical Technology?

Silexion Therapeutics (NASDAQ:SLXN) and Creative Medical Technology (NASDAQ:CELZ) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, media sentiment, profitability, risk, earnings, analyst recommendations, dividends and valuation.

Silexion Therapeutics has a beta of -0.32, meaning that its stock price is 132% less volatile than the broader market. Comparatively, Creative Medical Technology has a beta of 1.84, meaning that its stock price is 84% more volatile than the broader market.

In the previous week, Silexion Therapeutics had 1 more articles in the media than Creative Medical Technology. MarketBeat recorded 2 mentions for Silexion Therapeutics and 1 mentions for Creative Medical Technology. Silexion Therapeutics' average media sentiment score of 1.92 beat Creative Medical Technology's score of 1.92 indicating that Silexion Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Silexion Therapeutics	Very Positive
Creative Medical Technology	Very Positive

Creative Medical Technology's return on equity of -88.38% beat Silexion Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Silexion Therapeutics	N/A	-516.86%	-176.68%
Creative Medical Technology	N/A	-88.38%	-84.71%

Creative Medical Technology has higher revenue and earnings than Silexion Therapeutics. Creative Medical Technology is trading at a lower price-to-earnings ratio than Silexion Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Silexion Therapeutics	N/A	N/A	-$11.91M	-$80.50	N/A
Creative Medical Technology	$10K	788.10	-$5.99M	-$2.14	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Silexion Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Creative Medical Technology	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

11.0% of Silexion Therapeutics shares are owned by institutional investors. Comparatively, 1.4% of Creative Medical Technology shares are owned by institutional investors. 5.0% of Silexion Therapeutics shares are owned by company insiders. Comparatively, 1.7% of Creative Medical Technology shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

Silexion Therapeutics beats Creative Medical Technology on 7 of the 13 factors compared between the two stocks.

How does Silexion Therapeutics compare to ObsEva?

Silexion Therapeutics (NASDAQ:SLXN) and ObsEva (NASDAQ:OBSV) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, media sentiment, valuation, institutional ownership, earnings, dividends, analyst recommendations and profitability.

In the previous week, Silexion Therapeutics had 2 more articles in the media than ObsEva. MarketBeat recorded 2 mentions for Silexion Therapeutics and 0 mentions for ObsEva. Silexion Therapeutics' average media sentiment score of 1.92 beat ObsEva's score of 0.00 indicating that Silexion Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Silexion Therapeutics	Very Positive
ObsEva	Neutral

11.0% of Silexion Therapeutics shares are held by institutional investors. Comparatively, 17.5% of ObsEva shares are held by institutional investors. 5.0% of Silexion Therapeutics shares are held by company insiders. Comparatively, 14.4% of ObsEva shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

ObsEva's return on equity of -416.36% beat Silexion Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Silexion Therapeutics	N/A	-516.86%	-176.68%
ObsEva	N/A	-416.36%	-92.01%

Silexion Therapeutics is trading at a lower price-to-earnings ratio than ObsEva, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Silexion Therapeutics	N/A	N/A	-$11.91M	-$80.50	N/A
ObsEva	N/A	N/A	-$58.38M	-$0.92	N/A

Given ObsEva's higher possible upside, analysts plainly believe ObsEva is more favorable than Silexion Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Silexion Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
ObsEva	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Silexion Therapeutics has a beta of -0.32, indicating that its share price is 132% less volatile than the broader market. Comparatively, ObsEva has a beta of 0.68, indicating that its share price is 32% less volatile than the broader market.

Summary

ObsEva beats Silexion Therapeutics on 8 of the 13 factors compared between the two stocks.

How does Silexion Therapeutics compare to Nuvilex?

Silexion Therapeutics (NASDAQ:SLXN) and Nuvilex (NASDAQ:PMCB) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, media sentiment, earnings, valuation, institutional ownership, risk and dividends.

Silexion Therapeutics has a beta of -0.32, indicating that its stock price is 132% less volatile than the broader market. Comparatively, Nuvilex has a beta of 0.51, indicating that its stock price is 49% less volatile than the broader market.

Nuvilex's return on equity of 2.13% beat Silexion Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Silexion Therapeutics	N/A	-516.86%	-176.68%
Nuvilex	N/A	2.13%	1.69%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Silexion Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Nuvilex	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Nuvilex is trading at a lower price-to-earnings ratio than Silexion Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Silexion Therapeutics	N/A	N/A	-$11.91M	-$80.50	N/A
Nuvilex	N/A	N/A	$30.66M	-$1.12	N/A

11.0% of Silexion Therapeutics shares are owned by institutional investors. Comparatively, 34.2% of Nuvilex shares are owned by institutional investors. 5.0% of Silexion Therapeutics shares are owned by company insiders. Comparatively, 11.0% of Nuvilex shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

In the previous week, Silexion Therapeutics had 1 more articles in the media than Nuvilex. MarketBeat recorded 2 mentions for Silexion Therapeutics and 1 mentions for Nuvilex. Silexion Therapeutics' average media sentiment score of 1.92 beat Nuvilex's score of 1.87 indicating that Silexion Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Silexion Therapeutics	Very Positive
Nuvilex	Very Positive

Summary

Nuvilex beats Silexion Therapeutics on 7 of the 12 factors compared between the two stocks.

How does Silexion Therapeutics compare to NKGen Biotech?

Silexion Therapeutics (NASDAQ:SLXN) and NKGen Biotech (NYSE:NKGN) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, institutional ownership, earnings, media sentiment, profitability, analyst recommendations, risk and valuation.

11.0% of Silexion Therapeutics shares are owned by institutional investors. Comparatively, 76.2% of NKGen Biotech shares are owned by institutional investors. 5.0% of Silexion Therapeutics shares are owned by company insiders. Comparatively, 10.4% of NKGen Biotech shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Silexion Therapeutics has a beta of -0.32, indicating that its share price is 132% less volatile than the broader market. Comparatively, NKGen Biotech has a beta of 0.66, indicating that its share price is 34% less volatile than the broader market.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Silexion Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
NKGen Biotech	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

In the previous week, Silexion Therapeutics had 2 more articles in the media than NKGen Biotech. MarketBeat recorded 2 mentions for Silexion Therapeutics and 0 mentions for NKGen Biotech. Silexion Therapeutics' average media sentiment score of 1.92 beat NKGen Biotech's score of 0.21 indicating that Silexion Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Silexion Therapeutics	Very Positive
NKGen Biotech	Neutral

NKGen Biotech is trading at a lower price-to-earnings ratio than Silexion Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Silexion Therapeutics	N/A	N/A	-$11.91M	-$80.50	N/A
NKGen Biotech	N/A	N/A	-$82.94M	-$1.51	N/A

NKGen Biotech's return on equity of 0.00% beat Silexion Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Silexion Therapeutics	N/A	-516.86%	-176.68%
NKGen Biotech	N/A	N/A	-479.36%

Summary

Silexion Therapeutics and NKGen Biotech tied by winning 6 of the 12 factors compared between the two stocks.

Get Silexion Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SLXN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SLXN vs. The Competition

Export

Metric	Silexion Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$1.28M	$3.29B	$6.47B	$11.73B
Dividend Yield	N/A	2.33%	2.67%	5.56%
P/E Ratio	-0.04	19.62	24.43	24.09
Price / Sales	N/A	301.53	503.66	108.37
Price / Cash	N/A	120.36	43.20	54.62
Price / Book	0.37	8.21	10.50	6.82
Net Income	-$11.91M	$23.89M	$3.56B	$337.41M
7 Day Performance	-37.70%	-3.00%	-2.02%	-0.96%
1 Month Performance	-39.05%	-1.64%	0.66%	1.68%
1 Year Performance	-97.74%	40.20%	21.85%	26.88%

Silexion Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SLXN Silexion Therapeutics	1.1371 of 5 stars	$3.09 +1.0%	N/A	-97.8%	$1.28M	N/A	N/A	N/A	Positive News
ADXN Addex Therapeutics	0.5022 of 5 stars	$6.60 +3.2%	N/A	-20.8%	$8.12M	$210K	N/A	30	News Coverage Positive News Upcoming Earnings Gap Up
CELZ Creative Medical Technology	0.7733 of 5 stars	$2.16 -3.1%	N/A	-12.8%	$7.99M	$10K	N/A	5	Positive News
OBSV ObsEva	N/A	N/A	N/A	N/A	$7.94M	N/A	N/A	50
PMCB Nuvilex	1.5079 of 5 stars	$0.74 -2.0%	N/A	-35.2%	$7.91M	N/A	N/A	4

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:SLXN) was last updated on 6/11/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Silexion Therapeutics (SLXN) Competitors

SLXN vs. ADXN, CELZ, OBSV, PMCB, and NKGN

How does Silexion Therapeutics compare to Addex Therapeutics?

Summary

How does Silexion Therapeutics compare to Creative Medical Technology?

Summary

How does Silexion Therapeutics compare to ObsEva?

Summary

How does Silexion Therapeutics compare to Nuvilex?

Summary

How does Silexion Therapeutics compare to NKGen Biotech?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SLXN vs. The Competition

Silexion Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Silexion Therapeutics (SLXN) Competitors

SLXN vs. ADXN, CELZ, OBSV, PMCB, and NKGN

How does Silexion Therapeutics compare to Addex Therapeutics?

Which has more risk and volatility, SLXN or ADXN?

Which has higher earnings & valuation, SLXN or ADXN?

Does the media prefer SLXN or ADXN?

Is SLXN or ADXN more profitable?

Do insiders & institutionals hold more shares of SLXN or ADXN?

Do analysts recommend SLXN or ADXN?

Summary

How does Silexion Therapeutics compare to Creative Medical Technology?

Which has more risk and volatility, SLXN or CELZ?

Does the media refer more to SLXN or CELZ?

Is SLXN or CELZ more profitable?

Which has preferable earnings & valuation, SLXN or CELZ?

Do analysts recommend SLXN or CELZ?

Do institutionals and insiders believe in SLXN or CELZ?

Summary

How does Silexion Therapeutics compare to ObsEva?

Does the media refer more to SLXN or OBSV?

Do insiders & institutionals believe in SLXN or OBSV?

Is SLXN or OBSV more profitable?

Which has better earnings & valuation, SLXN or OBSV?

Do analysts rate SLXN or OBSV?

Which has more volatility and risk, SLXN or OBSV?

Summary

How does Silexion Therapeutics compare to Nuvilex?

Which has more volatility & risk, SLXN or PMCB?

Is SLXN or PMCB more profitable?

Do analysts rate SLXN or PMCB?

Which has higher earnings & valuation, SLXN or PMCB?

Do insiders and institutionals have more ownership in SLXN or PMCB?

Does the media refer more to SLXN or PMCB?

Summary

How does Silexion Therapeutics compare to NKGen Biotech?

Do institutionals and insiders believe in SLXN or NKGN?

Which has more volatility and risk, SLXN or NKGN?

Do analysts recommend SLXN or NKGN?

Does the media prefer SLXN or NKGN?

Which has stronger earnings & valuation, SLXN or NKGN?

Is SLXN or NKGN more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SLXN vs. The Competition

Silexion Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools